Navigation Links
Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
Date:11/16/2009

ALPHARETTA, Ga., Nov. 16 /PRNewswire/ -- Brookstone Pharmaceuticals, an emerging specialty pharmaceutical company, announced today its decision to change the name of the company to Acella Pharmaceuticals, LLC. This decision has been made to create a company image and brand that more accurately mirrors our commitment to "Accelerating the Health Care Solution" by bringing quality affordable products to customers and patients. Mark Pugh, CEO states, "As we have grown over the last few years, we have evolved into a more integrated pharmaceutical company. We believe this new name, Acella Pharmaceuticals, LLC, better aligns our company's image with our mission of delivering our customers the highest quality product at affordable prices."

The company will continue to operate as a specialty pharmaceutical company bringing value to our customer base while providing savings and choice to patients nationwide. Business contacts will remain unchanged and the company Labeler Code and National Drug Code (NDC) numbers remain unchanged. Our web domain will change to www.AcellaPharma.com.

If you have any immediate questions, please contact us at 678-325-5188.

SOURCE Brookstone Pharmaceuticals, LLC


'/>"/>
SOURCE Brookstone Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
2. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
3. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
6. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
10. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
11. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):